Literature DB >> 31786627

Secondary alterations in bone mineralisation and trabecular thickening occur after long-term estrogen deficiency in ovariectomised rat tibiae, which do not coincide with initial rapid bone loss.

L M O'Sullivan1, H Allison1, E E Parle1, J Schiavi1, L M McNamara2.   

Abstract

This study delineates the time sequence of changes in bone tissue mineralisation in ovariectomised rats. We report that changes in bone mineral distribution arise secondary to the initial rapid bone loss but coincide with trabecular thickening. We propose that these changes compensate for elevated stresses in remaining trabeculae after bone resorption.
INTRODUCTION: Recent studies have shown that osteoporosis is not simply a disease of bone loss and microarchitectural degradation but that important changes in tissue composition also occur. Such changes may be a secondary response to early bone loss, but the time sequence of changes in bone mineral distribution is not fully understood. The objective of this study was to quantify the temporal effects of estrogen deficiency on trabecular mineral distribution in the tibia of ovariectomised (OVX) rats.
METHODS: Weekly in vivo micro-CT scans and morphometric and bone mineral density distribution analyses of the proximal tibia were conducted for the first 4 weeks of estrogen deficiency and then at 8, 14 and 34 weeks.
RESULTS: Here we report that although trabecular bone volume and architecture are significantly deteriorated within the first 4 weeks of estrogen deficiency, there is no change in the distribution of bone mineral within trabeculae during this initial period. The rate of bone loss in OVX animals dramatically reduced between week 4 and week 14, which coincided with the initiation of increases in trabecular thickness and mineralisation in the OVX group.
CONCLUSIONS: Together this study reveals for the first time that alterations in bone mineralisation and trabecular thickening arise secondary to the initial rapid bone loss. We propose that these secondary mineralisation changes act to reinforce the trabecular network in an attempt to compensate for the increased loading that ensues after severe bone loss. This study provides an insight into temporal changes in bone mineral distribution in estrogen deficiency.

Entities:  

Keywords:  In vivo micro-CT; Mineral heterogeneity; Osteoporosis; Ovariectomised rat model; Trabecular morphology

Year:  2019        PMID: 31786627     DOI: 10.1007/s00198-019-05239-5

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  37 in total

1.  Structural mechanisms of trabecular bone loss in man.

Authors:  J E Compston; R W Mellish; P Croucher; R Newcombe; N J Garrahan
Journal:  Bone Miner       Date:  1989-07

2.  Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity.

Authors:  S Kousteni; T Bellido; L I Plotkin; C A O'Brien; D L Bodenner; L Han; K Han; G B DiGregorio; J A Katzenellenbogen; B S Katzenellenbogen; P K Roberson; R S Weinstein; R L Jilka; S C Manolagas
Journal:  Cell       Date:  2001-03-09       Impact factor: 41.582

3.  Acute changes in trabecular bone connectivity and osteoclast activity in the ovariectomized rat in vivo.

Authors:  N E Lane; J M Thompson; D Haupt; D B Kimmel; G Modin; J H Kinney
Journal:  J Bone Miner Res       Date:  1998-02       Impact factor: 6.741

4.  Bone loss dynamics result in trabecular alignment in aging and ovariectomized rats.

Authors:  Jan H Waarsing; Judd S Day; Jan A N Verhaar; Antwan G H Ederveen; Harrie Weinans
Journal:  J Orthop Res       Date:  2006-05       Impact factor: 3.494

5.  Effects of ageing, prolonged estrogen deficiency and zoledronate on bone tissue mineral distribution.

Authors:  M A Brennan; J P Gleeson; F J O'Brien; L M McNamara
Journal:  J Mech Behav Biomed Mater       Date:  2013-09-14

6.  Temporal changes in bone composition, architecture, and strength following estrogen deficiency in osteoporosis.

Authors:  Orlaith Brennan; Julia S Kuliwaba; T Clive Lee; Ian H Parkinson; Nicola L Fazzalari; Laoise M McNamara; Fergal J O'Brien
Journal:  Calcif Tissue Int       Date:  2012-10-18       Impact factor: 4.333

7.  FDA Guidelines and animal models for osteoporosis.

Authors:  D D Thompson; H A Simmons; C M Pirie; H Z Ke
Journal:  Bone       Date:  1995-10       Impact factor: 4.398

8.  No effects of in vivo micro-CT radiation on structural parameters and bone marrow cells in proximal tibia of wistar rats detected after eight weekly scans.

Authors:  Julienne E M Brouwers; Bert van Rietbergen; Rik Huiskes
Journal:  J Orthop Res       Date:  2007-10       Impact factor: 3.494

Review 9.  The laboratory rat as an animal model for osteoporosis research.

Authors:  Pavlos P Lelovas; Theodoros T Xanthos; Sofia E Thoma; George P Lyritis; Ismene A Dontas
Journal:  Comp Med       Date:  2008-10       Impact factor: 0.982

10.  Bone degeneration and recovery after early and late bisphosphonate treatment of ovariectomized wistar rats assessed by in vivo micro-computed tomography.

Authors:  J E M Brouwers; F M Lambers; J A Gasser; B van Rietbergen; R Huiskes
Journal:  Calcif Tissue Int       Date:  2008-02-20       Impact factor: 4.333

View more
  4 in total

Review 1.  Osteocytes and Estrogen Deficiency.

Authors:  Laoise M McNamara
Journal:  Curr Osteoporos Rep       Date:  2021-11-26       Impact factor: 5.096

2.  Temporal and spatial changes in bone mineral content and mechanical properties during breast-cancer bone metastases.

Authors:  Anneke S K Verbruggen; Elan C McCarthy; Roisin M Dwyer; Laoise M McNamara
Journal:  Bone Rep       Date:  2022-06-12

Review 3.  High resolution 3D structures of mineralized tissues in health and disease.

Authors:  Steve Weiner; Emeline Raguin; Ron Shahar
Journal:  Nat Rev Endocrinol       Date:  2021-03-23       Impact factor: 43.330

4.  Early effects of ovariectomy on bone microstructure, bone turnover markers and mechanical properties in rats.

Authors:  Xingman Guo; Xiyue Yu; Qianqian Yao; Jian Qin
Journal:  BMC Musculoskelet Disord       Date:  2022-04-02       Impact factor: 2.362

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.